THC
Tenet Healthcare Corp
Tenet Healthcare Corp historical holders
total: 5
Viking Global Investors Tenet Healthcare Corp transactions over time
- Total transactions:
- 11
- New positions:
- 3
- Sold out:
- 3
- Added:
- 3
- Reduced:
- 2
- Held since:
- 2023 Q2
- Held for:
- 2 quarters
- Latest activity:
- 2023 Q4
Ole Andreas Halvorsen has been an institutional investor in Tenet Healthcare Corp (THC) since 2021 Q1. According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any shares. The fund/company first acquired THC in 2021 Q1, initially purchasing about 1.46M shares. Ole Andreas Halvorsen later completely sold out the position and reinvested in THC again in 2023 Q2. Since the initial investment, Viking Global Investors has made 10 more transactions in this position.
When did Ole Andreas Halvorsen exit their THC position?
Ole Andreas Halvorsen no longer holds Tenet Healthcare Corp (THC). They sold off their entire position in 2023 Q4, closing out an investment that began in 2021 Q1.
When did Ole Andreas Halvorsen first invest in THC?
Ole Andreas Halvorsen first invested in Tenet Healthcare Corp (THC) in 2021 Q1 at the reported quarter-end price of $52.00 per share, acquiring 1,461,313 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for THC?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Tenet Healthcare Corp (THC) is approximately $71.38 per share. This represents their average reported price* across all buy transactions.
Has Ole Andreas Halvorsen reinvested in THC after selling?
Yes, Ole Andreas Halvorsen has shown renewed interest in Tenet Healthcare Corp (THC). After completely selling their position, they reinitiated an investment in 2023 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $71.38
- Weighted AVG sell price:
- $65.89
THC transactions history by Viking Global Investors
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q4
|
0.00%
|
0
|
$65.89
|
|
-100% (-1,025,840)
|
-0.27%
|
|
2023 Q3
|
0.27%
|
1,025,840
|
$65.89
|
$67,592,598
|
+181.98% (+662,040)
|
+0.18%
|
|
2023 Q2
|
0.12%
|
363,800
|
$81.38
|
$29,606,044
|
new
|
+0.12%
|
|
2022 Q4
|
0.00%
|
0
|
$51.58
|
|
-100% (-383,510)
|
-0.09%
|
|
2022 Q3
|
0.09%
|
383,510
|
$51.58
|
$19,781,000
|
new
|
+0.09%
|
|
2022 Q2
|
0.00%
|
0
|
$85.96
|
|
-100% (-2,233,647)
|
-0.78%
|
|
2022 Q1
|
0.78%
|
2,233,647
|
$85.96
|
$192,004,000
|
-30.44% (-977,594)
|
-0.24%
|
|
2021 Q4
|
0.76%
|
3,211,241
|
$81.69
|
$262,326,000
|
-4.25% (-142,615)
|
-0.03%
|
|
2021 Q3
|
0.61%
|
3,353,856
|
$66.44
|
$222,830,000
|
+47.15% (+1,074,674)
|
+0.2%
|
|
2021 Q2
|
0.46%
|
2,279,182
|
$66.99
|
$152,682,000
|
+55.97% (+817,869)
|
+0.17%
|
|
2021 Q1
|
0.23%
|
$52.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.